Staff Members - Benha University
Clinical significance of soluble programmed death-1(sPD-1) in rheumatoid arthritis patients: Relation to disease activity and functional status
The egyptian rheumatologist • 2015
Publication Information
Authors
Waleed A. Hassan a,*, Eman A. Baraka a, Nehad A. Fouad b
Keywords
Not Available
Journal
The egyptian rheumatologist
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background: Programmed cell death-1 (PD-1) is an immunoreceptor that negatively regulates
antigen receptor signaling and plays a critical role in the immunoregulation of autoimmune diseases.
Aim of the work: This study aimed to measure the plasma and synovial fluid levels of soluble programmed
death-1(sPD-1) in rheumatoid arthritis (RA) patients and to correlate them with the clinical
and laboratory characteristics, disease activity, functional status and radiological severity.
Patients and methods: We measured sPD-1 in the plasma (n=60) and synovial fluid (SF) samples
(n=24) from 60 RA patients and in the plasma from healthy control (n=30). In the patients, disease
activity score using 28 joint counts (DAS28) and the health assessment questionnaire (HAQ)
score were assessed; immunoglobulin-M rheumatoid factor (IgM-RF) titer, anti-cyclic citrullinated
peptide (anti-CCP) antibodies titer and C-reactive protein (CRP) levels were measured and total Sharp
score calculated.
Results: In RA patients both plasma and SF sPD-1 levels (1416.9±1037.9 pg/ml and
1503.9±1129.48 pg/ml respectively) were highly significantly increased compared to its plasma level
in the healthy control (165±26.11 pg/mL) (p
antigen receptor signaling and plays a critical role in the immunoregulation of autoimmune diseases.
Aim of the work: This study aimed to measure the plasma and synovial fluid levels of soluble programmed
death-1(sPD-1) in rheumatoid arthritis (RA) patients and to correlate them with the clinical
and laboratory characteristics, disease activity, functional status and radiological severity.
Patients and methods: We measured sPD-1 in the plasma (n=60) and synovial fluid (SF) samples
(n=24) from 60 RA patients and in the plasma from healthy control (n=30). In the patients, disease
activity score using 28 joint counts (DAS28) and the health assessment questionnaire (HAQ)
score were assessed; immunoglobulin-M rheumatoid factor (IgM-RF) titer, anti-cyclic citrullinated
peptide (anti-CCP) antibodies titer and C-reactive protein (CRP) levels were measured and total Sharp
score calculated.
Results: In RA patients both plasma and SF sPD-1 levels (1416.9±1037.9 pg/ml and
1503.9±1129.48 pg/ml respectively) were highly significantly increased compared to its plasma level
in the healthy control (165±26.11 pg/mL) (p